Vis enkel innførsel

dc.contributor.authorChalabianloo, Fatemeh
dc.contributor.authorFadnes, Lars T.
dc.contributor.authorJohansson, Kjell Arne
dc.contributor.authorHøiseth, Gudrun
dc.contributor.authorVold, Jørn Henrik
dc.contributor.authorKringen, Marianne K.
dc.contributor.authorSpigset, Olav
dc.contributor.authorBramness, Jørgen Gustav
dc.date.accessioned2024-02-22T10:58:24Z
dc.date.available2024-02-22T10:58:24Z
dc.date.issued2023-12-20
dc.description.abstractBackground: A considerable inter-individual variability has been reported in the relationship between methadone doses applied and serum concentrations achieved in methadone maintenance treatment. However, the underlying causes for this variability are not fully understood.<p> <p>Objectives: We investigated the influence of genetic, pathophysiological and pharmacological factors on serum methadone concentration-to-dose ratio (CDR) and discussed the clinical implications of the findings. <p>Methods: We used data from two retrospective laboratory databases and a prospective cohort study to investigate the impact on methadone CDR of hepatic cytochrome P450 enzyme system (CYP) genetic polymorphisms, age, sex, concomitant medication, liver fibrosis and body mass index through linear mixed model analyses. <p>Findings: A positive association was found between CDR and the homozygous CYP2B6*6 genotype, concurrent treatment with CYP3A4 inhibitors and body mass index. CDR was lower among women and during concomitant use of CYP inducers. CDR was not associated with age or the degree of liver fibrosis in our investigations. <p>Conclusions: This research work supports the need for individually tailored dosage considering the various factors that influence methadone CDR. The gained knowledge can contribute to reducing the risks associated with the treatment and optimizing the desired outcomes.en_US
dc.identifier.citationChalabianloo F, Fadnes LT, Johansson KA, Høiseth G, Vold JH, Kringen MKK, Spigset, Bramness JG. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Basic & Clinical Pharmacology & Toxicology. 2024;134(3):333-344en_US
dc.identifier.cristinIDFRIDAID 2234015
dc.identifier.doi10.1111/bcpt.13975
dc.identifier.issn1742-7835
dc.identifier.issn1742-7843
dc.identifier.urihttps://hdl.handle.net/10037/33010
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalBasic & Clinical Pharmacology & Toxicology
dc.relation.projectIDHelse Vest RHF: F-11328-912126en_US
dc.relation.projectIDNorges forskningsråd: 269855en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleMethadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implicationsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)